000170124 001__ 170124
000170124 005__ 20260318155255.0
000170124 0247_ $$2doi$$a10.1080/14737167.2023.2256473
000170124 0248_ $$2sideral$$a148535
000170124 037__ $$aART-2023-148535
000170124 041__ $$aeng
000170124 100__ $$aAndreu Crespo, M.A.
000170124 245__ $$aCost-effectiveness of somatrogon in the Spanish pediatric population with growth hormone deficiency
000170124 260__ $$c2023
000170124 5060_ $$aAccess copy available to the general public$$fUnrestricted
000170124 5203_ $$aObjective: To analyze the cost-effectiveness of weekly somatrogon compared to daily growth hormones (GH-d) in the pediatric population of Spain with growth hormone deficiency (GHD).
Methods: Markov model with two states (patients with or without GH-d or somatrogon treatment) in prepubertal children (3 to 11 years and 3 to 12 years in girls and boys, respectively) with GHD in isolation or as part of multiple pituitary hormone deficiency and without previous treatment, from the perspective of the National Health System. The simulation of the economic model ends at the age of 18. The costs of hormones and monitoring were obtained from Spanish sources. The utilities were obtained from the literature. Spanish clinical experts validated the assumptions of the model.
Results: In the deterministic analysis, somatrogon would be cost-effective, compared to GH-d, with a cost per QALY (quality-adjusted life year) gained of €19,259 and a clinically relevant QALY gain (0.336). This result was confirmed in deterministic sensitivity analyses. According to the probabilistic analysis, somatrogon would be the dominant treatment, with a 61% probability of a willingness to pay of €25,000 per QALY gained.
Conclusion: Compared to GH-d, somatrogon is cost-effective in the Spanish pediatric population with GHD.
000170124 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
000170124 590__ $$a1.8$$b2023
000170124 591__ $$aHEALTH CARE SCIENCES & SERVICES$$b101 / 174 = 0.58$$c2023$$dQ3$$eT2
000170124 591__ $$aHEALTH POLICY & SERVICES$$b72 / 118 = 0.61$$c2023$$dQ3$$eT2
000170124 591__ $$aPHARMACOLOGY & PHARMACY$$b240 / 354 = 0.678$$c2023$$dQ3$$eT3
000170124 592__ $$a0.671$$b2023
000170124 593__ $$aHealth Policy$$c2023$$dQ2
000170124 593__ $$aPharmacology (medical)$$c2023$$dQ2
000170124 593__ $$aMedicine (miscellaneous)$$c2023$$dQ2
000170124 594__ $$a4.0$$b2023
000170124 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000170124 700__ $$aCastro-Feijóo, L.
000170124 700__ $$0(orcid)0000-0003-2832-2266$$aLabarta-Aizpún, J.I.$$uUniversidad de Zaragoza
000170124 700__ $$aPeral, C.
000170124 700__ $$aBarrueta, J.A.
000170124 700__ $$aRubio-Rodríguez, D.
000170124 700__ $$aRubio-Terres, C.
000170124 7102_ $$11011$$2670$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Pediatría
000170124 773__ $$g23, 10 (2023), 1139-1146$$pExpert Review of Pharmacoeconomics and Outcomes Research$$tExpert Review of Pharmacoeconomics and Outcomes Research$$x1473-7167
000170124 8564_ $$s2247214$$uhttps://zaguan.unizar.es/record/170124/files/texto_completo.pdf$$yVersión publicada
000170124 8564_ $$s1138470$$uhttps://zaguan.unizar.es/record/170124/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000170124 909CO $$ooai:zaguan.unizar.es:170124$$particulos$$pdriver
000170124 951__ $$a2026-03-18-13:52:48
000170124 980__ $$aARTICLE